Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 5 AND DEXTROSE 7 5 versus ROPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 5 AND DEXTROSE 7 5 versus ROPIVACAINE HYDROCHLORIDE.
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% vs ROPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking the initiation and conduction of nerve impulses. Dextrose provides caloric support.
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
For IV administration, typical adult dose is 5-7 mg/kg intravenously as a single bolus, followed by 0.5-1 mg/kg every 5-10 minutes as needed, up to a maximum total dose of 200-300 mg. For epidural or caudal anesthesia, 15-20 mL of the 5% solution provides adequate block. For peripheral nerve block, 10-30 mL. Do not exceed 5 mg/kg per dose intravenously or 300 mg per dose by infiltration.
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in healthy adults after intravenous administration. In patients with heart failure or hepatic impairment, half-life may be prolonged to 4-6 hours or more. After epidural administration, half-life may be slightly longer due to ongoing absorption.
Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance.
Renal excretion of unchanged lidocaine and metabolites; less than 10% excreted unchanged in urine. Hepatic metabolism produces active metabolites (MEGX, GX) which are renally excreted. Biliary/fecal excretion negligible.
Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor.
Category A/B
Category A/B
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic